2. Academic Validation
  3. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides

  • Bioorg Med Chem Lett. 2003 Feb 10;13(3):567-71. doi: 10.1016/s0960-894x(02)00918-6.
Stuart W McCombie 1,  Jayaram R Tagat,  Susan F Vice,  Sue-Ing Lin,  Ruo Steensma,  Anandan Palani,  Bernard R Neustadt,  Bahige M Baroudy,  Julie M Strizki,  Michael Endres,  Kathleen Cox,  Niya Dan,  Chuan-Chu Chou
Affiliations

Affiliation

  • 1 Schering-Plough Research Institute, 2015 Galloping Hill Road, K-15-2B-2800, Kenilworth, NJ 07033, USA.
PMID: 12565973 DOI: 10.1016/s0960-894x(02)00918-6
Abstract

The unsymmetrical nicotinamide-N-oxide moiety in compound 1 was replaced with symmetrical isonicotinamides as well as 4,6-dimethyl pyrimidine-5-carboxamides. Compound 16 from the latter set reduced the number of rotamers, improved potency of inhibiting UIV entry, slightly diminished the affinity for the muscarine receptors and showed very good oral absorption.

Figures